上海创新药研发生态形成外资企业、本土生物医药科技企业和国有医药企业三股力量,共同推动上海成为具有全球影响力的生物医药创新高地。截至目前,上海2025年有9个1类创新药获批上市。其中,12月9日,上海上药信谊药厂有限公司申报的1类创新药苹果酸司妥吉仑片(商品名称:信妥安)获国家药监局批准上市,成为上海今年第9个获批上市的一类创新药。该药适用于原发性高血压,和传统降压药相比,上药研发团队经过多年不断...
Source Link上海创新药研发生态形成外资企业、本土生物医药科技企业和国有医药企业三股力量,共同推动上海成为具有全球影响力的生物医药创新高地。截至目前,上海2025年有9个1类创新药获批上市。其中,12月9日,上海上药信谊药厂有限公司申报的1类创新药苹果酸司妥吉仑片(商品名称:信妥安)获国家药监局批准上市,成为上海今年第9个获批上市的一类创新药。该药适用于原发性高血压,和传统降压药相比,上药研发团队经过多年不断...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.